ERAS compared with MAZE: revenue, margins and what each company keeps, and the suppliers and customers both name

ERASErasca, Inc.

Mkt capRevenueRevenue

MAZEMaze Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ERASErasca, Inc.

MAZEMaze Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

ERASErasca, Inc.

14.33▼−4.34%· post 14.20

Mkt cap$5.0BRevenue—

MAZEMaze Therapeutics, Inc.

31.42▼−1.60%· post 31.10

ClosedOct 30 '26

Mkt cap$1.9BRevenue$20MQ1 FY26

Compare

ClosedOct 30 '26

ERASErasca, Inc.

MAZEMaze Therapeutics, Inc.

14.33▼−4.34%post 14.20

Price

31.42▼−1.60%post 31.10

$5.0B

Mkt cap

$1.9B

—

Revenue

$20MQ1 FY26

ERAS14.33▼−4.34%vsMAZE31.42▼−1.60%ClosedOct 30 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

ERAS, solidMAZE, dashed

Supply-chain overlap

Revenue flow

ERAS: latest quarter not drawable. MAZE: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ERAS 5

—Emerge Life Sciences, Pteunlistedsupplier

—Guangzhou Joyo Pharmatechunlistedsupplier

—Medshine Discoveryunlistedsupplier

—Novartis Pharmaunlistedsupplier

1 more · ERAS chain ›

Shared 0

No shared counterparties.

Only MAZE 4

NBIXNeurocrine Biosciencescustomer

—Shionogiunlistedcustomer

—Trace Neuroscienceunlistedcustomer

—

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Alloy Therapeutics

unlistedcustomer